Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma
4/30/2012 10:25:23 AM
More...
|
Florida Biologix(R) Announces Manufacturing Agreement with Altor BioScience Corporation
6/28/2011 11:34:34 AM
More...
|
Altor BioScience Corporation Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI
5/23/2011 8:37:26 AM
More...
|
Altor BioScience Corporation Awarded $3 MM SBIR Bridge Grant by National Cancer Institute to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801
9/25/2009 8:05:15 AM
More...
|
Altor BioScience Corporation Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital
9/10/2008 8:55:20 AM
More...
|
Altor BioScience Corporation In-Licenses Tissue Factor Antagonists from Genentech, Inc. (DNA)
2/12/2008 8:43:00 AM
More...
|
Altor BioScience Corporation Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
12/20/2007 9:23:21 AM
More...
|
Altor BioScience Corporation Awarded Phase II SBIR Grant For Anti-Cancer Antibody Manufacture In Transgenic Plants
7/25/2006 10:21:00 AM
More...
|
Altor BioScience Corporation Introduces STAR(TM) Multimer Reagents To Measure Disease-Specific Antigen Presentation
3/13/2006 11:49:41 AM
More...
|
Altor BioScience Corporation Establishes Collaboration With Leading Massachusetts General Hospital Investigator To Develop TCR-based Agents To Detect And Treat HIV And HCV Infection
10/19/2005 5:12:24 PM
More...
|
|